BeiGene (NASDAQ:BGNE) PT Raised to $236.00 at TD Cowen

BeiGene (NASDAQ:BGNE) had its target price upped by equities research analysts at TD Cowen from $235.00 to $236.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s price objective points to a potential upside of 58.86% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. Guggenheim lowered their target price on shares of BeiGene from $350.00 to $345.00 and set a “buy” rating for the company in a research note on Tuesday, February 27th. Sanford C. Bernstein lowered their price objective on BeiGene from $196.00 to $161.00 and set a “market perform” rating for the company in a research report on Wednesday, March 27th. JPMorgan Chase & Co. upped their target price on BeiGene from $184.00 to $186.00 and gave the company an “overweight” rating in a research report on Tuesday, March 19th. Finally, Bank of America lowered their target price on BeiGene from $179.30 to $164.30 and set a “neutral” rating for the company in a report on Monday, April 8th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $250.13.

BeiGene Trading Up 3.1 %

NASDAQ BGNE opened at $148.56 on Wednesday. BeiGene has a 12 month low of $126.97 and a 12 month high of $266.67. The company has a current ratio of 2.32, a quick ratio of 2.09 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $14.21 billion, a PE ratio of -17.48 and a beta of 0.61. The business’s 50-day moving average price is $154.73 and its two-hundred day moving average price is $167.40.

BeiGene (NASDAQ:BGNE) last announced its earnings results on Monday, February 26th. The company reported ($3.53) EPS for the quarter, beating the consensus estimate of ($3.61) by $0.08. BeiGene had a negative return on equity of 23.12% and a negative net margin of 35.86%. The business had revenue of $634.40 million for the quarter, compared to analysts’ expectations of $632.52 million. During the same period in the prior year, the business posted ($4.29) earnings per share. The firm’s revenue was up 66.9% on a year-over-year basis. On average, analysts expect that BeiGene will post -8.87 EPS for the current year.

Insider Buying and Selling at BeiGene

In other news, CEO John Oyler sold 37,668 shares of BeiGene stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $164.02, for a total transaction of $6,178,305.36. Following the completion of the transaction, the chief executive officer now directly owns 12,332 shares in the company, valued at $2,022,694.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO John Oyler sold 37,668 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $164.02, for a total value of $6,178,305.36. Following the transaction, the chief executive officer now owns 12,332 shares in the company, valued at $2,022,694.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Julia Aijun Wang sold 397 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $167.08, for a total value of $66,330.76. The disclosure for this sale can be found here. In the last 90 days, insiders sold 64,781 shares of company stock worth $10,222,381. 7.40% of the stock is owned by corporate insiders.

Institutional Trading of BeiGene

Several institutional investors and hedge funds have recently made changes to their positions in BGNE. Knights of Columbus Asset Advisors LLC grew its position in BeiGene by 20.5% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 447 shares of the company’s stock worth $80,000 after purchasing an additional 76 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in shares of BeiGene by 4.8% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 1,704 shares of the company’s stock valued at $306,000 after acquiring an additional 78 shares in the last quarter. NewEdge Wealth LLC increased its position in shares of BeiGene by 7.5% during the fourth quarter. NewEdge Wealth LLC now owns 1,612 shares of the company’s stock valued at $291,000 after acquiring an additional 112 shares during the last quarter. Vestmark Advisory Solutions Inc. lifted its holdings in BeiGene by 9.5% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 1,601 shares of the company’s stock worth $289,000 after acquiring an additional 139 shares during the period. Finally, Parkwood LLC boosted its position in BeiGene by 3.0% in the fourth quarter. Parkwood LLC now owns 6,464 shares of the company’s stock worth $1,166,000 after purchasing an additional 191 shares during the last quarter. Hedge funds and other institutional investors own 48.55% of the company’s stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.